AdaptHealth's Q2 Miss Has a Simple Explanation - the Business the Market Is Still Pricing Was Already Sold

AdaptHealth reported Q2 2026 results today with headline numbers that look like a breakdown on the surface. The company posted a GAAP EPS loss of $1.07, missing consensus by $1.22, while revenue came in at $740.3 million, well below the roughly $846.8 million analysts expected. But the headline miss has a specific mechanical cause: AdaptHealth agreed to sell its Diabetes Health business to Cardinal Health for $235 million in cash late last month, and that unit's revenue is no longer part of the core picture. The market is still pricing a company that can't hit its numbers. The portfolio reshaping suggests the numbers the market should care about are just becoming visible.

AdaptHealth has been on a multi-year portfolio surgery. CEO Suzanne Foster announced the diabetes divestiture as the latest and most significant step in focusing the company on its core sleep, respiratory, and supporting home medical equipment businesses. This follows three prior divestitures. The diabetes business operated primarily as a centralized, mail-order, direct-to-patient model delivering supplies like continuous glucose monitors to over 225,000 people annually. The format and economics don't match the in-home clinical services that define AdaptHealth's stronger franchises. Selling it to Cardinal Health, which already operates at scale in this distribution model, is a logical fit.

The revenue miss of roughly $106 million maps directly to the lost diabetes contribution. The consensus estimate of around $847 million was built before the July 19 divestiture agreement and included the diabetes segment. Strip that out, and the core revenue runs roughly in line with what the business should be doing. Q1 2026 total revenue was $819.8 million, which included diabetes. If the diabetes unit contributed approximately $100 million per quarter - consistent with a $235 million cash sale price for a stable, low-margin mail-order operation - then the Q1 core revenue base was about $720 million. The $740 million Q2 core number would represent roughly 3% sequential organic growth in the businesses AdaptHealth actually intends to keep.

The GAAP EPS miss is more about accounting scars than operating performance. AdaptHealth took a $128 million non-cash goodwill impairment in the fourth quarter of 2025, which wrecked GAAP earnings for the prior period. The company has been losing money on a GAAP basis while generating solid operating cash. Full-year 2025 cash flow from operations was $601.8 million - an increase year over year - and free cash flow reached $219.4 million. The business produces cash. The question is whether the reshaped portfolio produces more of it with less complexity.

On that front, the directional evidence points the right way. Patient census set records in Sleep Health, Respiratory Health, and Wellness at Home during the fourth quarter, and management signaled continued growth. The company also secured the largest capitated contract in the industry's history - a fixed-fee arrangement where AdaptHealth gets paid a set amount per patient rather than per device or supply, which aligns incentives and smooths revenue. The company invested in critical infrastructure and nearly 500 dedicated employees to begin onboarding this contract in Q4 2025, with the ramp continuing through 2026. Capitated contracts are harder to execute but more defensible once established, because they lock in patient volume and reduce the per-claim billing friction that characterizes traditional Medicare reimbursement for home medical equipment.

The $235 million in cash from the diabetes sale adds another inflection vector. AdaptHealth closed 2025 with $250 million in debt reduction and received credit upgrades from both S&P and Moody's. Deploying the diabetes proceeds toward further debt paydown accelerates the deleveraging trajectory and reduces interest drag on free cash flow. The company guided full-year 2026 free cash flow of $175 million to $225 million, against a backdrop of net revenue guidance of $3.44 billion to $3.51 billion and adjusted EBITDA of $680 million to $730 million. That guidance was issued before the divestiture, so the post-divestiture free cash flow range should be higher - the company gets $235 million in cash while losing only the diabetes segment's adjusted EBITDA contribution, which as a low-margin mail-order business was likely a modest contributor relative to its revenue.

The market is still pricing the old story. AHCO trades near $10.80, with a market capitalization around $1.5 billion. That implies roughly seven times the guided 2026 adjusted EBITDA midpoint of $705 million. For a home medical equipment operator with the structural tailwinds of an aging population and a Medicare-driven reimbursement system that favors consolidation, that multiple reflects a company the market still doubts. The Q1 EPS miss of –$0.12 against a near-zero estimate, followed by a nearly 10% stock drop, shows the reflex. Investors see another miss and anchor to the pattern rather than recalibrating to the portfolio that's actually being built.

The one proof point that matters most over the next 12 months is whether the post-divestiture core - sleep, respiratory, and supporting HME - generates free cash flow at or above the guided range while the capitated contract ramps. If core revenue continues its roughly 3% sequential pace and adjusted EBITDA margins improve as the company sheds the lower-margin diabetes operation, the free cash flow run rate moves meaningfully higher. The $235 million in diabetes proceeds acts as an accelerator, not a replacement. Simple math: if 2026 core free cash flow hits the $175M to $225M range and the diabetes cash reduces net debt by the full $235 million, the leverage profile and interest burden both improve materially versus the original guidance assumption.

The setup is not without risk. Capitated contracts require heavy upfront investment before they become accretive, and AdaptHealth already spent more than $10 million in Q4 2025 on onboarding costs. If the ramp is slower than planned, the investment drag extends into 2027. The home medical equipment reimbursement environment remains subject to Medicare audit pressure and pricing negotiations, which can compress margins faster than management models. And the core revenue growth rate of roughly 1.7% organic in full-year 2025 is not fast - it's adequate, and the question is whether it accelerates once the portfolio cleanup is complete and the capitated volume scales.

This is not an argument for buying the headline. It's an argument that the headline is stale. The market is pricing AdaptHealth as a company that misses estimates and can't execute. The portfolio is being reshaped into something narrower and arguably cleaner: fewer business lines, higher-margin in-home services, a massive capitated contract that should provide revenue visibility, and $235 million in cash to reduce debt. If that execution path holds, the seven-times-adjusted-EBITDA multiple looks like the market still pricing the diabetes business that's already being sold.

What would prove the thesis wrong is simple. If core revenue - excluding diabetes - fails to grow sequentially through the second half of 2026, or if adjusted EBITDA falls meaningfully below the guided range once the diabetes segment is removed, then the portfolio surgery is just cutting revenue without improving quality. The capitated contract ramp would be the first place to check. If the patient volume doesn't materialize on the timeline management has signaled, the upfront investment becomes a drag rather than an inflection. That's the tripwire: core growth stalls and the free cash flow bridge breaks.